A Phase 1 interventional study of pitavastatin and pitavastatin single dose combined with ceftobiprole in Drug-drug Interaction Study, sponsored by Basilea Pharmaceutica. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by Basilea Pharmaceutica · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical study was to determine the effect of the test drug ceftobiprole (a drug approved for the treatment of bacterial infections) on the elimination of pitavastatin (a drug approved for the treatment of increased levels of cholesterol in blood) from the body. This interaction was investigated by pharmacokinetic (PK) assessments. The clinical study also investigated the safety of ceftobiprole and how well ceftobiprole was tolerated by healthy subjects when it was administered in combination with pitavastatin.
This study assessed whether there was an inhibitory effect of ceftobiprole on hepatic organic anion-transporting polypeptide 1B (OATP1B) activity. Pitavastatin was used as an OATP1B substrate in this study. The pharmacokinetics of oral pitavastatin were assessed when administered alone and when administered together with IV ceftobiprole in a study design including 2 treatment periods. In addition, the pharmacodynamic effect of repeated doses of IV ceftobiprole on the diurnal plasma levels of coproporphyrin I (CP-I) was assessed in this study as CP-I is an endogenous biomarker for hepatic OATPB1 activity.
The study duration was up to 38 days.
Basilea Pharmaceutica is the lead sponsor of 60 studies on the registry; 7 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 15 (68%) have results posted.
Counted across the registry records on this site, refreshed daily.
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On Day 1, a single oral dose of pitavastatin was administered
Drug: pitavastatin
From Day 4 to Day 7, ceftobiprole (as the prodrug ceftobiprole medocaril sodium) will be administered intravenously (IV) every 8 hours (q8h) for four days. On Day 6, a single oral dose of pitavastatin will be co-administered with ceftobiprole From Day 4 to Day 7, 500 mg ceftobiprole (as the prodrug ceftobiprole medocaril sodium) was administered as a 2-hour IV dose every 8 hours (q8h) under fasted conditions in the morning, and irrespective of timing of food intake further on the day. On Day 6, a single oral dose of 2 mg pitavastatin was co-administered with ceftobiprole 30 minutes prior to the end of the first IV dose of 500 mg ceftobiprole under fasted conditions.
Drug: pitavastatin single dose combined with ceftobiprole
Single oral administration
Single oral pitavastatin co-administered with IV ceftobiprole
Maximum Observed Plasma Concentration (Cmax) of Pitavastatin
To assess the pharmacokinetic parameter Cmax in plasma after a single oral dose of pitavastatin administered without and with intravenous (IV) ceftobiprole
Time frame: Sampling on Day 1 and Day 6; before dosing, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 hours (h) post-dose. Day 2 and Day 7; 24 and 36 h post-dose. Day 3 and Day 8; 48 h post-dose
Area Under the Plasma Concentration-time Curve up to Time (AUC0-t) After Pitavastatin Administration
To assess the pharmacokinetic parameter AUC0-t after a single oral dose of pitavastatin administered without and with IV ceftobiprole
Time frame: Sampling on Day 1 and Day 6; before dosing, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 hours (h) post-dose. Day 2 and Day 7; 24 and 36 h post-dose. Day 3 and Day 8; 48 h post-dose
Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) After Pitavastatin Administration
To assess the pharmacokinetic parameter AUC0-inf after a single oral dose of pitavastatin administered without and with IV ceftobiprole
Time frame: Sampling on Day 1 and Day 6; before dosing, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 hours (h) post-dose. Day 2 and Day 7; 24 and 36 h post-dose. Day 3 and Day 8; 48 h post-dose
Cmax of Coproporphyrin I (CP-I)
The pharmacokinetic parameter Cmax for CP-I in plasma was assessed with and without administration of IV ceftobiprole
Time frame: Sampling on Day 5; pre-dose, 2, 4, 6, 8 h, 16, and 25.5 (Day 6) hours post-dose and corresponding samples on Day -1
Area Under the Plasma Level-time Curve up to Time 25.5 Hours (AUEC0-25.5h) of CP-I in Plasma
The pharmacokinetic parameter AUEC0-25.5h for CP-I was assessed with and without administration of IV ceftobiprole
Time frame: Sampling on Day 5; pre-dose, 2, 4, 6, 8 h, 16, and 25.5 (Day 6) hours post-dose and corresponding samples on Day -1
Cmax of Ceftobiprole in Plasma
To assess the pharmacokinetic parameter Cmax of IV ceftobiprole without and with oral administration of pitavastatin
Time frame: Sampling on Day 5: pre-dose ,1, 2, 4, 6, 8 h post-dose, on Day 6; pre-dose,1, 2, 4, 6, 8 h post-dose
Area Under the Plasma Concentration-time Curve up to 8 Hours (AUC0-8h) After IV Ceftobiprole
To assess the pharmacokinetic parameter AUC0-8h after IV ceftobiprole without and with oral administration of pitavastatin
Time frame: Sampling on Day 5: pre-dose ,1, 2, 4, 6, 8 h post-dose, on Day 6; pre-dose,1, 2, 4, 6, 8 h post-dose
Cmax of the Pitavastatin Metabolite Pitavastatin Lactone in Plasma After Pitavastatin Administration
To assess the pharmacokinetic parameter Cmax of pitavastatin lactone after a single oral dose of pitavastatin administered without and with IV ceftobiprole
Time frame: Sampling on Day 1 and Day 6; before dosing, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 hours (h) post-dose. Day 2 and Day 7; 24 and 36 h post-dose. Day 3 and Day 8; 48 h post-dose
AUC0-t of the Pitavastatin Metabolite Pitavastatin Lactone in Plasma After Pitavastatin Administration
To assess the pharmacokinetic parameter AUC0-t of pitavastatin lactone after a single oral dose of pitavastatin administered without and with IV ceftobiprole
Time frame: Sampling on Day 1 and Day 6; before dosing, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 hours (h) post-dose. Day 2 and Day 7; 24 and 36 h post-dose. Day 3 and Day 8; 48 h post-dose
AUC0-inf of of the Pitavastatin Metabolite Pitavastatin Lactone in Plasma After Pitavastatin Administration
To assess the pharmacokinetic parameter AUC0-inf of pitavastatin lactone after a single oral dose of pitavastatin administered without and with IV ceftobiprole
Time frame: Sampling on Day 1 and Day 6; before dosing, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 hours (h) post-dose. Day 2 and Day 7; 24 and 36 h post-dose. Day 3 and Day 8; 48 h post-dose
Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) After Administration of Ceftobiprole Without and With a Single Oral Dose of Pitavastatin
A treatment-emergent AE (TEAE) was defined as any event not present prior to the first administration of the study drug, or any event already present that worsens in either severity or frequency following exposure to the study drug
Time frame: Up to 17 days after first dosing; Pitavastatin Period 1 between first dose on Day1 and before first dose on Day4; ceftobiprole Period 2 between first dose on Day4 and before first dose on Day6; pitavastatin + ceftopibrole Period 2 after first dose on Day6
Twelve (12) subjects were enrolled in the study and completed the study as per protocol. The study was conducted in one research center in the Netherlands.
| Milestone | Entire Population of Subjects |
|---|---|
| Started | 12 |
| Completed | 12 |
| Not completed | 0 |
To assess the pharmacokinetic parameter Cmax in plasma after a single oral dose of pitavastatin administered without and with intravenous (IV) ceftobiprole
| ng/mL | Period 1; Pitavastatin 2 mg | Period 2; Pitavastatin 2 mg Combined With Ceftobiprole 500 mg |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Pitavastatin | 42.79 (12.80 to 98.70) | 33.54 (8.69 to 98.70) |
To assess the pharmacokinetic parameter AUC0-t after a single oral dose of pitavastatin administered without and with IV ceftobiprole
| ng x h/mL | Period 1; Pitavastatin 2 mg | Period 2; Pitavastatin 2 mg Combined With Ceftobiprole 500 mg |
|---|---|---|
| Area Under the Plasma Concentration-time Curve up to Time (AUC0-t) After Pitavastatin Administration | 100.29 (32.7 to 235.0) | 86.63 (39.1 to 226.5) |
To assess the pharmacokinetic parameter AUC0-inf after a single oral dose of pitavastatin administered without and with IV ceftobiprole
| ng x h/mL | Period 1; Pitavastatin 2 mg | Period 2; Pitavastatin 2 mg Combined With Ceftobiprole 500 mg |
|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) After Pitavastatin Administration | 105.42 (35.3 to 241.4) | 91.59 (42.0 to 232.5) |
The pharmacokinetic parameter Cmax for CP-I in plasma was assessed with and without administration of IV ceftobiprole
| ng/mL | Without Ceftobiprole | With Ceftobiprole |
|---|---|---|
| Cmax of Coproporphyrin I (CP-I) | 0.41 (0.26 to 0.58) | 0.42 (0.26 to 0.61) |
The pharmacokinetic parameter AUEC0-25.5h for CP-I was assessed with and without administration of IV ceftobiprole
| ng x h/mL | Without Ceftobiprole | With Ceftobiprole |
|---|---|---|
| Area Under the Plasma Level-time Curve up to Time 25.5 Hours (AUEC0-25.5h) of CP-I in Plasma | 9.08 (5.24 to 13.44) | 9.27 (4.84 to 13.73) |
To assess the pharmacokinetic parameter Cmax of IV ceftobiprole without and with oral administration of pitavastatin
| ng/mL | Day 5: Ceftobiprole Alone | Day 6: Ceftobiprole + Pitavastatin |
|---|---|---|
| Cmax of Ceftobiprole in Plasma | 26361 (21200 to 33600) | 27423 (22100 to 32600) |
To assess the pharmacokinetic parameter AUC0-8h after IV ceftobiprole without and with oral administration of pitavastatin
| ng x h/mL | Day 5: Ceftobiprole Alone | Day 6: Ceftobiprole + Pitavastatin |
|---|---|---|
| Area Under the Plasma Concentration-time Curve up to 8 Hours (AUC0-8h) After IV Ceftobiprole | 104204 (74322 to 136270) | 105623 (80376 to 140904) |
To assess the pharmacokinetic parameter Cmax of pitavastatin lactone after a single oral dose of pitavastatin administered without and with IV ceftobiprole
| ng/mL | Period 1; Pitavastatin 2 mg | Period 2; Pitavastatin 2 mg Combined With Ceftobiprole 500 mg |
|---|---|---|
| Cmax of the Pitavastatin Metabolite Pitavastatin Lactone in Plasma After Pitavastatin Administration | 15.91 (8.15 to 20.80) | 14.39 (9.44 to 20.40) |
To assess the pharmacokinetic parameter AUC0-t of pitavastatin lactone after a single oral dose of pitavastatin administered without and with IV ceftobiprole
| ng x h/mL | Period 1; Pitavastatin 2 mg | Period 2; Pitavastatin 2 mg Combined With Ceftobiprole 500 mg |
|---|---|---|
| AUC0-t of the Pitavastatin Metabolite Pitavastatin Lactone in Plasma After Pitavastatin Administration | 181.18 (94.0 to 304.1) | 157.11 (107.0 to 229.4) |
To assess the pharmacokinetic parameter AUC0-inf of pitavastatin lactone after a single oral dose of pitavastatin administered without and with IV ceftobiprole
| ng x h/mL | Period 1; Pitavastatin 2 mg | Period 2; Pitavastatin 2 mg Combined With Ceftobiprole 500 mg |
|---|---|---|
| AUC0-inf of of the Pitavastatin Metabolite Pitavastatin Lactone in Plasma After Pitavastatin Administration | 196.73 (101.5 to 361.7) | 171.60 (122.1 to 248.0) |
A treatment-emergent AE (TEAE) was defined as any event not present prior to the first administration of the study drug, or any event already present that worsens in either severity or frequency following exposure to the study drug
| Participants | Pitavastatin Period 1 | Ceftobiprole Period 2 | Pitavastatin + Ceftobiprole Period 2 |
|---|---|---|---|
| Any serious TEAE | 0 | 0 | 0 |
| Any non-serious TEAE | 5 | 7 | 5 |
| Not any TEAE | 7 | 5 | 7 |
Collected over Up to 17 days after first dosing; Pitavastatin Period 1 between first dose on Day1 and before first dose on Day4; ceftobiprole Period 2 between first dose on Day4 and before first dose on Day6; pitavastatin + ceftopibrole Period 2 after first dose on Day6. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pitavastatin Period 1 | 0/12 (0%) | 0/12 (0%) | 5/12 (41.7%) |
| Ceftobiprole Period 2 | 0/12 (0%) | 0/12 (0%) | 7/12 (58.3%) |
| Pitavastatin + Ceftobiprole Period 2 | 0/12 (0%) | 0/12 (0%) | 5/12 (41.7%) |
| Event | Pitavastatin Period 1 | Ceftobiprole Period 2 | Pitavastatin + Ceftobiprole Period 2 |
|---|---|---|---|
| Catheter site irritationGeneral disorders | 2/12 | 1/12 | 3/12 |
| DysgeusiaNervous system disorders | 2/12 | 1/12 | 2/12 |
| HeadacheNervous system disorders | 0/12 | 1/12 | 2/12 |
| DiarrhoeaGastrointestinal disorders | 2/12 | 2/12 | 0/12 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/12 | 1/12 | 1/12 |
| Abdominal distensionGastrointestinal disorders | 1/12 | 0/12 | 0/12 |
| Abdominal painGastrointestinal disorders | 1/12 | 0/12 | 0/12 |
| NauseaGastrointestinal disorders | 0/12 | 1/12 | 1/12 |
| GastroenteritisInfections and infestations | 0/12 | 0/12 | 1/12 |
| Catheter site haematomaGeneral disorders | 0/12 | 0/12 | 1/12 |
| Age, Continuous(years) | Entire Population of Subjects |
|---|---|
| Mean | 40.4 ± 15.36 |
| Sex: Female, Male(Participants) | Entire Population of Subjects |
|---|---|
| Female | 6 |
| Male | 6 |
| Race/Ethnicity, Customized(Participants) | Entire Population of Subjects |
|---|---|
| White | 11 |
| Other | 1 |
| Height (cm)(cm) | Entire Population of Subjects |
|---|---|
| Mean | 174.8 ± 7.50 |
| Weight (kg)(kg) | Entire Population of Subjects |
|---|---|
| Mean | 76.67 ± 12.51 |
| BMI(kg/m2) | Entire Population of Subjects |
|---|---|
| Mean | 25.00 ± 3.06 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2025 to primary completion in Feb 2025, 1 month.
Results were first posted in Apr 2026, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pitavastatin